Day: July 8, 2021

Subsea 7 agrees to combine its Renewables business unit with OHT Luxembourg – 8 July 2021  Conference call for investors The management of Subsea 7 and OHT will hold an investor conference in relation to the transaction on Thursday 8th July at 9am UK (10am CEST). Date:                          8 July 2021Time:                         09:00 UK time Dial in numbers:UK                                0844-481-9752USA                              646-741-3167Norway                         21-56-30-15International dial in:        +44-20-7192-8338 Conference ID:                9197607 Lines will open 15 minutes prior to the conference call.A live webcast and a playback facility will be available on the Subsea 7 website: www.Subsea7.com *******************************************************************************Subsea 7 is a global leader...

ORION CORPORATION STOCK EXCHANGE RELEASE 8 JULY 2021 at 9.00 EEST          32,884 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 32,884 A shares have been converted into 32,884 B shares. The conversion has been entered into the Trade Register on 8 July 2021. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 35,006,523 A shares and 106,127,755 B shares. The number of votes of the company’s shares is after the conversion 806,258,215. Orion CorporationJari Karlson CFO     Olli Huotari SVP, Corporate Functions                                                  Contact person:Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200...

Telenor Group has entered into an agreement to sell 100 percent of its mobile operations in Myanmar to M1 Group for a total consideration of 105 million USD (approximately 900 million NOK), of which 55 million USD (approximately 470 million NOK) is a deferred payment over five years. The transaction corresponds to an implied enterprise value of approximately 600 million USD (approximately 5.2 billion NOK). M1 Group will acquire all the shares in Telenor Myanmar and continue the current operation.  On 4 May, Telenor Group announced an impairment of Telenor Myanmar. Telenor underlined at the time that the operations in Myanmar continued, and that the future presence would depend on the developments in the country and the ability to contribute positively to the people of Myanmar. Further deterioration of the situation and recent developments...

Ensovibep maintains potency in an in vitro assay and demonstrated full inhibition of all newly emerging known variants of concern, including the Delta variants of concern EMPATHY Phase 2/3 trial enrolling ambulatory patients in 5 countries with more countries to be added in the coming months, with interim data expected in H2 2021 and full topline data expected in early 2022 ACTIV-3, a Phase 3 trial enrolling hospitalized patients across 4 countries with more countries expected to be added in the coming months, with topline data expected in 2022 Subcutaneous formulation on track for initiation of clinical trials in H2 2021ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) — Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new...

Marks first European launches of Maxigesic IV, a well-tolerated and effective non-opioid pain treatment          Liège, Belgium – 8 July 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product globally. Maxigesic IV is currently licensed in more than 100 countries across the globe, and it has been...